Merck & Co. (MRK) : Eastern Bank reduced its stake in Merck & Co. by 0.68% during the most recent quarter end. The investment management company now holds a total of 252,751 shares of Merck & Co. which is valued at $14,917,364 after selling 1,732 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Jul 15, 2016.Merck & Co. makes up approximately 1.17% of Eastern Bank’s portfolio.
Other Hedge Funds, Including , Gwm Advisors added MRK to its portfolio by purchasing 6,307 company shares during the most recent quarter which is valued at $372,239. Merck & Co. makes up approx 0.15% of Gwm Advisors’s portfolio.Hartford Financial Management reduced its stake in MRK by selling 150 shares or 0.52% in the most recent quarter. The Hedge Fund company now holds 28,599 shares of MRK which is valued at $1,705,358. Merck & Co. makes up approx 0.99% of Hartford Financial Management’s portfolio.Abner Herrman Brock boosted its stake in MRK in the latest quarter, The investment management firm added 5,787 additional shares and now holds a total of 271,452 shares of Merck & Co. which is valued at $16,164,967. Merck & Co. makes up approx 3.74% of Abner Herrman Brock’s portfolio.Peachtree Investment Advisors reduced its stake in MRK by selling 760 shares or 4.56% in the most recent quarter. The Hedge Fund company now holds 15,922 shares of MRK which is valued at $948,155. Merck & Co. makes up approx 0.95% of Peachtree Investment Advisors’s portfolio.Marshwinds Advisory Co reduced its stake in MRK by selling 762 shares or 1.11% in the most recent quarter. The Hedge Fund company now holds 67,856 shares of MRK which is valued at $4,027,254. Merck & Co. makes up approx 1.95% of Marshwinds Advisory Co’s portfolio.
Merck & Co. closed down -0.61 points or -1.02% at $59.02 with 87,69,171 shares getting traded on Monday. Post opening the session at $59, the shares hit an intraday low of $58.715 and an intraday high of $59.49 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.